Filana Therapeutics (FLNA) Gains from Investment Securities (2024)
Filana Therapeutics (FLNA) posted quarterly Gains from Investment Securities of $65.1 million for Q2 2024, up 51.35% quarter-over-quarter from $43.0 million in Q1 2024.
Filana Therapeutics (FLNA) Gains from Investment Securities (2024) Analysis & Trends
Filana Therapeutics' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $65.1 million for Q2 2024.
- In Q2 2024, Gains from Investment Securities changed N/A year-over-year to $65.1 million; the TTM figure through Mar 2025 stood at $65.1 million (up 51.35% YoY), while the FY2024 annual figure was -$108.2 million, changed N/A from the prior year.
- Gains from Investment Securities for Q2 2024 stood at $65.1 million, up from $43.0 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $65.1 million in Q2 2024, with the low at $43.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 65.14 Mn |
| Jun 30, 2024 | 65.14 Mn |
| Mar 31, 2024 | 43.04 Mn |
| Mar 31, 2024 | 43.04 Mn |